## **ICMJE DISCLOSURE FORM**

Date:			5/12/2022			
Your Name:			Margreet G.E.M. Ausems			
Manuscript Title:			Leerartikel Oncogenetica			
Manuscript Number (if known):			D6958			
In the interest of transparency, we content of your manuscript. "Rela affected by the content of the mai indicate a bias. If you are in doubt The author's relationships/activities."			e ask you to disclose all relationships/activities/interests listed below that are related to the ated" means any relation with for-profit or not-for-profit third parties whose interests may be nuscript. Disclosure represents a commitment to transparency and does not necessarily t about whether to list a relationship/activity/interest, it is preferable that you do so.  es/interests should be defined broadly. For example, if your manuscript pertains to the u should declare all relationships with manufacturers of antihypertensive medication, even if			
-	t medication is not m	-				
				ithout time limit. For all other items, the time		
			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
			Time frame: Since the initial planning o	of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing,	⊠ No	one			
	article processing			Click the tab key to add additional rows.		
	article processing charges, etc.)			Click the tab key to add additional rows.		
	article processing			Click the tab key to add additional rows.		
	article processing charges, etc.) No time limit for		Time frame: past 36 months			
2	article processing charges, etc.) No time limit for	Pfizer C	Time frame: past 36 months  ne  nkerbestrijding prostate cancer  Oncology breast cancer project eneca breast cancer project			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	Astellas Pharma B.V Meridian HealthComms AstraZeneca/ MSD	Payment to institution Payment to institution Payment to me
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None None	
7	Support for attending meetings and/or travel	None     ■	
8	Patents planned, issued or pending	None □	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	□ None	

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options		None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None		
13	Other financial or non-financial interests		None		
Please place an "X" next to the following statement to indicate your agreement:  \[ \sum I certify that I have answered every question and have not altered the wording of any of the questions on this form.					